Based on cytotoxic T lymphocyte (CTL) epitopes from CMV pp65, the principal CTL target for CMV, a novel candidate lipopeptide vaccine has been developed. It is composed of the HLA A*0201-restricted CTL epitope from pp65 covalently attached to a powerful synthetic T-helper epitope, and lipidated at the amino terminus. The test-of-concept for this novel lipopeptide CMV vaccine has been shown using an HLA A2.1 transgenic murine model. The goal of this project is to characterize the immune response to CMV in persons treated with HAART (highly active anti-retroviral therapy) and determine if this immunity can be boosted by lipopeptide immunization. In a three-way collaboration, the City of Hope team will conduct the in vitro measurements of immunity; and the team at the Los Angeles County Medical Center/University of Southern California (LAC/USC) will identify patients, obtain specimens for in vitro measurements, and vaccinate eligible patients. The third team, Peninsula Laboratories, will be responsible for the synthesis and production of lipopeptide vaccine under FDA-approved conditions. Individuals with HIV infection will be studied to understand the cellular immune response to CMV. Information not currently known despite the fact that CMV-associated diseases, including retinitis, enteritis, and encephalitis have been a leading cause of morbidity and mortality in this population, and that CMV could be linked to HIV progression. These studies are important because of the need to explain recent reports indicating less CMV disease with HAART, but the occasional case of CMV retinitis despite recovery to >200 CD4+ T cell counts. At LAC/USC, approximately 70% of new AIDS clinic patients are naive to HAART and will be evaluated for changing CMV immune repertoire during the course of HAART treatment and CD4+ T cell recovery. These studies are aimed at discovering whether immunoprophylaxis against CMV is possible or warranted in individuals undergoing HAART. The strategy of immunization in the setting of HIV-1 infection and HAART in patients with diverse DLA alleles will be built upon a concurrent demonstration of the clinical efficacy of the HLA A2.1-restricted CMV pp65 lipopeptide vaccine in patient volunteers.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043267-02
Application #
2887759
Study Section
Special Emphasis Panel (ZRG5-ARRD (05))
Program Officer
Laughon, Barbara E
Project Start
1998-06-05
Project End
2002-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Zhu, He; Stybayeva, Gulnaz; Silangcruz, Jaime et al. (2009) Detecting cytokine release from single T-cells. Anal Chem 81:8150-6
Gallez-Hawkins, Ghislaine; Thao, Lia; Lacey, Simon F et al. (2005) Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biol Blood Marrow Transplant 11:890-902
Villacres, Maria C; Literat, Oana; Degiacomo, Marina et al. (2005) Reduced type 1 and type 2 cytokines in antiviral memory T helper function among women coinfected with HIV and HCV. J Clin Immunol 25:134-41
Gibson, Laura; Piccinini, Giampiero; Lilleri, Daniele et al. (2004) Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 172:2256-64
Villacres, Maria C; Longmate, Jeff; Auge, Catherine et al. (2004) Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol 65:476-85
Gallez-Hawkins, Ghislaine; Li, Xiuli; Franck, Anne E et al. (2004) DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine 23:819-26
Lacey, Simon F; Diamond, Don J; Zaia, John A (2004) Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 10:433-47
Gallez-Hawkins, Ghislaine; Villacres, Maria C; Li, Xiuli et al. (2003) Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J Virol 77:4457-62
Lacey, Simon F; Villacres, Maria C; La Rosa, Corinna et al. (2003) Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64:440-52
Daftarian, Pirouz; Ali, Saima; Sharan, Rahul et al. (2003) Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J Immunol 171:4028-39

Showing the most recent 10 out of 18 publications